Foreign Direct Investment in China Continues to Fall
Foreign direct investment in China dropped in the first two months of the year, continuing a fall that started after economic growth plateaued amid a prolonged property downturn and weak domestic demand
China attracted 215.1 billion yuan ($29.88 billion) of foreign direct investment in the first two months of the year, down 19.9% from a year ago, the Ministry of Commerce said on Friday.
The ministry said the latest data was dwarfed by the record-high level a year earlier.
"Despite the decline this year, it is still at the third highest level in the past 10 years," the ministry said.
In 2023, foreign investment in the world's second largest economy dropped 8.0% from the previous year in yuan terms. It stopped releasing data in dollar terms last year.
The ministry tried to downplay the decline, saying "foreign investment is a market behavior and data fluctuations are normal and in line with market rules."
It also said China's advantages in attracting investment, including its large market, complete supply chain and infrastructure and abundant human resources, still outweighed unfavorable factors.
The number of newly established foreign-funded enterprises reached 7,160 in the first two months, up 34.9% on year and the highest level in the past five years, the ministry added.
Write to Singapore Editors at singaporeeditors@dowjones.com
(END) Dow Jones Newswires
March 22, 2024 06:35 ET (10:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand